Acquisitions (Details) - USD ($) |
12 Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 05, 2024 |
Dec. 15, 2023 |
Oct. 03, 2023 |
Sep. 30, 2023 |
Sep. 29, 2023 |
Apr. 19, 2023 |
Dec. 31, 2024 |
Dec. 31, 2023 |
Sep. 30, 2024 |
Jun. 13, 2024 |
Apr. 24, 2024 |
Apr. 19, 2024 |
|
| Acquisitions [Line Items] | ||||||||||||
| Paid transaction | $ 6,000,000 | |||||||||||
| Non-interest bearing note payable | $ 4,000,000 | $ 5,000,000 | $ 5,000,000 | $ 10,000,000 | ||||||||
| Royalty sales percentage | 6.00% | |||||||||||
| Sales payments amount | $ 22,500,000 | |||||||||||
| Payment to seller | $ 1,000,000 | |||||||||||
| Converted shares (in Shares) | 500,000 | |||||||||||
| Stockholder issuance term | 1 year | |||||||||||
| Fair value adjustments | 300,000 | |||||||||||
| Acquired inventory | $ 12,947,000 | |||||||||||
| Business acquisition, description | (i) $3.5 million in cash at signing of the WraSer APA; (ii) $4.5 million in cash on the later of (x) 90 days after the signing of the WraSer APA or (y) the date that all closing conditions under the WraSer APA are met or otherwise waived (the “WraSer Closing Date”); (iii) 25,000 shares of the Company’s common stock (the “Closing Shares”) issuable on the WraSer Closing Date, and (iv) $500,000 in cash one year from the WraSer Closing Date. | |||||||||||
| Cash payment amount | $ 500,000 | |||||||||||
| Initial payment amount | $ 3,500,000 | |||||||||||
| Company payments | 3,500,000 | |||||||||||
| Payment as deposit | 3,500,000 | |||||||||||
| Cash target amount | $ 1,100,000 | |||||||||||
| Voting interest percentage | 100.00% | |||||||||||
| Issuance of common stock (in Shares) | 91,885 | |||||||||||
| Milestone Payments are payable | i) the Company obtained 100% of the outstanding common stock and voting interest of PMX, (ii) at closing of the PMX Transaction, the PMX shareholders were issued approximately 17% of Onconetix’s outstanding common stock and none of the former PMX shareholders held more than 5% of Onconetix’s common stock individually, (iii) the composition of executive management and the governing body did not change sufficiently to give PMX or its former shareholders control over these functions within Onconetix, and (iv) Onconetix was significantly larger when considering both total assets and operations. | |||||||||||
| Royalty rate | 6.00% | |||||||||||
| Fair value of non controlling interest | 2,613,011 | |||||||||||
| Related costs | 1,500,000 | |||||||||||
| Customer Relationships [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Discount rate, percentage | 10.00% | |||||||||||
| Trade Names [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Discount rate, percentage | 10.00% | |||||||||||
| Product Rights Developed Technology [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Discount rate, percentage | 7.00% | |||||||||||
| Discount rate thereafter | 14.00% | |||||||||||
| Veru APA [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Note payable | $ 4,000,000 | |||||||||||
| Note payable originally due | Sep. 30, 2023 | |||||||||||
| Notes Payable [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Non interest | 8.20% | |||||||||||
| Management Services Agreement [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Cash payment amount | $ 4,500,000 | |||||||||||
| WraSer APA [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Business acquisition, description | (i) $2.2 million to be paid at closing, (ii) $2.3 million, to be paid in monthly installments of $150,000 commencing January 2024 and (iii) 789 shares of Series A Preferred Stock to be paid at closing | |||||||||||
| Cash payment amount | $ 4,500,000 | |||||||||||
| Bankruptcy Court [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Business acquisition, description | The amendment also reduced the number of products the Company was acquiring by excluding pain medications and including only (i) Ciprofloxacin 0.3% and Fluocinolone 0.025% Otic Solution, under the trademark OTOVEL and its Authorized Generic Version approved under US FDA NDA No. 208251, (ii) Ciprofloxacin 0.2% Otic solution, under the trademark CETRAXAL, and (iii) Vorapaxar Sulfate tablets under the trademark Zontivity approved under US FDA NDA N204886. | |||||||||||
| WraSer MSA [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Payment as deposit | 3,500,000 | |||||||||||
| Asset Purchase Agreement [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Consideration amount | 100,000,000 | |||||||||||
| ENTADFI [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Consideration amount | $ 20,000,000 | |||||||||||
| Business acquisition payable description | (i) $10.0 million is payable upon the first time the Company achieves net sales from ENTADFI® of $100.0 million during a calendar year, (ii) $20.0 million is payable upon the first time the Company achieves net sales from ENTADFI of $200.0 million during a calendar year, and (3) $50.0 million is payable upon the first time the Company achieves net sales from ENTADFI of $500.0 million during a calendar year. | |||||||||||
| Impairment charge | $ 3,500,000 | 14,700,000 | ||||||||||
| Acquired inventory | $ 400,000 | 1,200,000 | ||||||||||
| Percentage of impairment | 100.00% | |||||||||||
| Milestone Payments [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Consideration amount | $ 80,000,000 | |||||||||||
| Pharmaceutical Services, LLC [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Business acquisition payable description | (i) $5.0 million is payable upon the first time the Company achieves net sales from ENTADFI of $100.0 million during a calendar year, (ii) $7.5 million is payable upon the first time the Company achieves net sales from ENTADFI of $200.0 million during a calendar year, and (3) $10.0 million is payable upon the first time the Company achieves net sales from ENTADFI of $300.0 million during a calendar year. | |||||||||||
| WraSer [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Initial payment | $ 3,500,000 | |||||||||||
| PMX Transaction [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Consideration transferred total | $ 65,100,000 | |||||||||||
| Proteomedix [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Fair value of non controlling interest | $ 7,000,000 | |||||||||||
| Series A Convertible Preferred Stock [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Converted shares (in Shares) | 3,000 | |||||||||||
| Shares of common stock (in Shares) | 0 | 3,000 | ||||||||||
| Series A Preferred Stock [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Shares of common stock (in Shares) | 3,000 | |||||||||||
| Series A Preferred Stock [Member] | Common Stock [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Shares of common stock (in Shares) | 142,479 | |||||||||||
| Series B Convertible Preferred Stock [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Issuance of common stock (in Shares) | 2,696,729 | |||||||||||
| Series B Preferred Stock [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Number of shares (in Shares) | 100 | |||||||||||
| Series B Preferred Stock [Member] | PMX Transaction [Member] | ||||||||||||
| Acquisitions [Line Items] | ||||||||||||
| Issuance of common stock (in Shares) | 6,741,820 | 6,741,820 | ||||||||||